Chorionic gonadotropin, vials of 1000 units, 5 ml, 5 pcs.

Active substance:

chorionic gonadotropin 1000 units

Chorionic gonadotropin is a gonadotropic hormone. It is produced by the human placenta and excreted in the urine, from where it can be extracted and purified. Stimulates the production of progesterone by the corpus luteum and supports the development of the placenta. It has a gonadotropic effect, mainly luteinizing.

In women, the drug induces ovulation and stimulates the synthesis of estrogen and progesterone. In men, it stimulates spermatogenesis and the production of sex steroids.

Pharmacokinetics

After i / m administration, it is well absorbed. T1 / 2 is 8 hours.

It is believed that before excretion in the urine, chorionic gonadotropin is modified in the body, because its T1 / 2, measured by the immunological method, significantly exceeds this indicator, determined by biological activity.

For women: 

Ovulation induction after stimulating follicular growth; 

Maintenance of the function of the corpus luteum of the ovary in patients with luteal phase insufficiency.

For boys and men: 

Cryptorchidism (ectopia, retention of the testicles in the abdominal cavity or in the inguinal canal);

Delayed puberty; 

Hypogonadotropic hypogonadism (in combination with drugs of human menopausal gonadotropin);

When conducting a differential diagnostic test of anorchism and cryptorchidism in boys; 

When performing the Leydig functional test to assess testicular function in hypogonadotropic hypogonadism before starting long-term stimulating treatment.

• Tumors of various localization, dependent on sex hormones; 
• Organically caused cryptorchidism (inguinal hernia, the consequences of surgical interventions in the groin area, incorrect position of the testicles) in boys and men; 
• Hypersensitivity to human chorionic gonadotropin.

On the part of the endocrine system in women: it is possible to develop ovarian hyperstimulation syndrome, accompanied by the development of ovarian cysts with the danger of rupture, ascites, hydrothorax and the risk of thromboembolism.

On the part of the endocrine system in boys and men: possible temporary reversible enlargement of the mammary glands, prostate gland, water and electrolyte retention, acne vulgaris; 

Boys may experience behavioral changes similar to those observed during the first phase of puberty, which disappear after the end of treatment.

Chorionic gonadotropin is prescribed intramuscularly. The dose is individualized depending on the nature, severity of the disease and the age of the patient and ranges from 500 to 3000 U per day.

For men, the drug is administered 2-3 times a week in courses of 4 weeks at intervals of 4-6 weeks. 3-6 courses are carried out within 6-12 months. Long-term continuous use of the drug is not recommended due to the risk of antibody formation and suppression of the gonadotropic function of the pituitary gland.

With anovulatory cycles with a high level of estrogen in women, which indicates the normal maturation of follicles, the drug is administered starting from the 10-12th day of the cycle, 3000 U 2-3 times with an interval of 2-3 days or 1500 U 6-7 times in one day.

With interstitial pituitary insufficiency, treatment with chorionic gonadotropin is best carried out after preliminary treatment in the first phase of the cycle with follicle-stimulating hormone. With pituitary dwarfism with symptoms of sexual infantilism, the drug is administered at a dose of 500-1000 IU 1-2 times a week for 1-2 months by repeated courses.

Chorionic gonadotropin treatment of cryptorchidism in children is most effective under the age of 10 years. The dosage and duration of treatment are individual, depending on the location of the undescended testicle and the nature of cryptorchidism (unilateral or bilateral).

The most common treatment regimen is as follows: for cryptorchidism in children under the age of 10 years, 500-1000 units are administered, at the age of 10-14 years - 1500 units 2 times a week for 4-6 weeks by repeated courses.

For diagnostic purposes, the drug is administered to men at 1500-3000 IU per day for 5 days. With a positive test result, the daily urinary excretion of 17-ketosteroids and testosterone increases.

Lyophilized powder for preparation of injection solution